• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠肺炎患者的死亡率与近期肺炎支原体感染的关系。

Association of mortality and recent Mycoplasma pneumoniae infection in COVID-19 patients.

机构信息

Department of Medicine, Hoboken University Medical Center, Hoboken, New Jersey, USA.

Department of Pediatrics, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Med Virol. 2021 Feb;93(2):1180-1183. doi: 10.1002/jmv.26467. Epub 2020 Sep 29.

DOI:10.1002/jmv.26467
PMID:32852080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7461379/
Abstract

To compare characteristics and outcomes of patients who had COVID-19 with Mycoplasma pneumoniae immunoglobulin M (IgM) antibodies to those without M. pneumoniae antibodies. We retrospectively reviewed cases admitted over a 4-week period between 17 March 2020 and 14 April 2020 to the Hoboken University Medical Center, NJ, USA. We compared the outcomes of COVID-19 patients who were positive for M. pneumoniae IgM with those who were negative for M. pneumoniae IgM. The primary outcome was mortality. The adjusted odds ratio was calculated after controlling for baseline differences. Of 139 patients admitted with COVID-19, 79 were positive for M. pneumoniae IgM. The mortality among those who were M. pneumoniae IgM positive was significantly higher (adjusted odds ratio: 2.28, 95% confidence interval: 1.03 to 5.03) compared with those who were M. pneumoniae IgM negative. Patients with coinfection (COVID-19 and mycoplasma) have higher mortality compared with patients with just COVID-19 disease.

摘要

比较 COVID-19 患者与肺炎支原体免疫球蛋白 M(IgM)抗体阳性和阴性患者的特征和结局。我们回顾性分析了 2020 年 3 月 17 日至 4 月 14 日期间美国新泽西州霍博肯大学医学中心住院的 4 周内的病例。我们比较了肺炎支原体 IgM 阳性的 COVID-19 患者与肺炎支原体 IgM 阴性患者的结局。主要结局是死亡率。在控制基线差异后计算了调整后的优势比。在 139 名因 COVID-19 住院的患者中,有 79 名肺炎支原体 IgM 阳性。肺炎支原体 IgM 阳性患者的死亡率明显更高(调整后的优势比:2.28,95%置信区间:1.03 至 5.03),而肺炎支原体 IgM 阴性患者的死亡率则较低。合并感染(COVID-19 和支原体)的患者与仅患有 COVID-19 疾病的患者相比,死亡率更高。

相似文献

1
Association of mortality and recent Mycoplasma pneumoniae infection in COVID-19 patients.新冠肺炎患者的死亡率与近期肺炎支原体感染的关系。
J Med Virol. 2021 Feb;93(2):1180-1183. doi: 10.1002/jmv.26467. Epub 2020 Sep 29.
2
Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents.血清肺炎支原体IgA、IgM和IgG在学龄儿童及青少年肺炎支原体相关肺炎诊断中的作用
Clin Vaccine Immunol. 2017 Jan 5;24(1). doi: 10.1128/CVI.00471-16. Print 2017 Jan.
3
[Utility and limitation of the rapid IgM antibody detection test for the diagnosis of Mycoplasma pneumoniae infection].[快速IgM抗体检测试验在肺炎支原体感染诊断中的应用与局限性]
Kansenshogaku Zasshi. 2007 Mar;81(2):149-54. doi: 10.11150/kansenshogakuzasshi1970.81.149.
4
Age-specific Mycoplasma pneumoniae pneumonia-associated myocardial damage in children.儿童特定年龄组肺炎支原体肺炎相关心肌损伤
J Int Med Res. 2013 Oct;41(5):1716-23. doi: 10.1177/0300060513497559. Epub 2013 Sep 11.
5
Mycoplasma pneumoniae DNA detection and specific antibody class response in patients from two tertiary care hospitals in tropical Sri Lanka.热带斯里兰卡两家三级护理医院患者肺炎支原体 DNA 检测和特异性抗体类别反应。
J Med Microbiol. 2018 Sep;67(9):1232-1242. doi: 10.1099/jmm.0.000813. Epub 2018 Aug 3.
6
Atypical bacterial co-infections among patients with COVID-19: A study from India.COVID-19 患者中的非典型细菌合并感染:来自印度的研究。
J Med Virol. 2022 Jan;94(1):303-309. doi: 10.1002/jmv.27324. Epub 2021 Sep 15.
7
COVID-19 and Mycoplasma pneumoniae: SARS-CoV-2 false positive or coinfection?新型冠状病毒肺炎与肺炎支原体:严重急性呼吸综合征冠状病毒2假阳性还是合并感染?
Int J Dermatol. 2020 Oct;59(10):1282-1283. doi: 10.1111/ijd.15090. Epub 2020 Aug 7.
8
Chlamydophila pneumoniae serology: cross-reaction with Mycoplasma pneumoniae infection.肺炎衣原体血清学:与肺炎支原体感染的交叉反应。
J Infect Chemother. 2013 Apr;19(2):256-60. doi: 10.1007/s10156-012-0494-4. Epub 2012 Oct 13.
9
Clinical significance of Mycoplasma pneumoniae specific IgM titer in children hospitalized with Mycoplasma pneumoniae pneumonia.儿童肺炎支原体肺炎住院患者肺炎支原体特异性 IgM 滴度的临床意义。
BMC Infect Dis. 2022 May 16;22(1):470. doi: 10.1186/s12879-022-07456-6.
10
Diagnosis of Mycoplasma pneumoniae pneumonia in children.儿童支原体肺炎的诊断
J Clin Microbiol. 1998 Nov;36(11):3155-9. doi: 10.1128/JCM.36.11.3155-3159.1998.

引用本文的文献

1
A pilot study of the impact of bacterial and fungal coinfections on mildly ill COVID-19 patients.细菌和真菌合并感染对轻症COVID-19患者影响的一项初步研究。
Can J Respir Ther. 2025 Aug 12;61:182-190. doi: 10.29390/001c.142509. eCollection 2025.
2
Assessing and Reassessing the Association of Comorbidities and Coinfections in COVID-19 Patients.评估和重新评估新冠病毒肺炎患者合并症和合并感染之间的关联
Cureus. 2023 Mar 25;15(3):e36683. doi: 10.7759/cureus.36683. eCollection 2023 Mar.
3
Surveillance of Influenza and Other Airborne Transmission Viruses during the 2021/2022 Season in Hospitalized Subjects in Tuscany, Italy.意大利托斯卡纳地区2021/2022季节住院患者中流感及其他空气传播病毒的监测
Vaccines (Basel). 2023 Mar 31;11(4):776. doi: 10.3390/vaccines11040776.
4
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors.严重 COVID-19 的风险因素:宿主、病毒和环境因素的综述。
Viruses. 2023 Jan 7;15(1):175. doi: 10.3390/v15010175.
5
Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: Incidence, diagnosis and treatment.新型冠状病毒病 2019(COVID-19)相关细菌合并感染:发生率、诊断和治疗。
J Microbiol Immunol Infect. 2022 Dec;55(6 Pt 1):985-992. doi: 10.1016/j.jmii.2022.09.006. Epub 2022 Oct 7.
6
Identification of Coinfections by Viral and Bacterial Pathogens in COVID-19 Hospitalized Patients in Peru: Molecular Diagnosis and Clinical Characteristics.秘鲁新冠住院患者中病毒和细菌病原体合并感染的鉴定:分子诊断与临床特征
Antibiotics (Basel). 2021 Nov 7;10(11):1358. doi: 10.3390/antibiotics10111358.
7
Atypical bacterial co-infections among patients with COVID-19: A study from India.COVID-19 患者中的非典型细菌合并感染:来自印度的研究。
J Med Virol. 2022 Jan;94(1):303-309. doi: 10.1002/jmv.27324. Epub 2021 Sep 15.
8
Coinfections with Bacteria, Fungi, and Respiratory Viruses in Patients with SARS-CoV-2: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎患者合并细菌、真菌及呼吸道病毒感染:一项系统评价与Meta分析
Pathogens. 2021 Jun 25;10(7):809. doi: 10.3390/pathogens10070809.
9
Microbial co-infections in COVID-19: Associated microbiota and underlying mechanisms of pathogenesis.新型冠状病毒肺炎中的微生物共感染:相关共生菌群及发病机制的潜在机制。
Microb Pathog. 2021 Jul;156:104941. doi: 10.1016/j.micpath.2021.104941. Epub 2021 May 4.
10
The Complexity of Co-Infections in the Era of COVID-19.COVID-19时代合并感染的复杂性
SN Compr Clin Med. 2021;3(7):1502-1514. doi: 10.1007/s42399-021-00913-4. Epub 2021 Apr 23.

本文引用的文献

1
Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA.分析美国 COVID-19 合并肺炎支原体感染患者的特征、合并症和结局。
J Med Virol. 2020 Oct;92(10):2181-2187. doi: 10.1002/jmv.26026. Epub 2020 May 25.
2
Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.新冠病毒肺炎患者的狼疮抗凝物与异常凝血检测
N Engl J Med. 2020 Jul 16;383(3):288-290. doi: 10.1056/NEJMc2013656. Epub 2020 May 5.
3
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区,5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
4
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.新型冠状病毒病中“细胞因子风暴”的发病机制与治疗。
J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.
5
Sixty-eight consecutive patients assessed for COVID-19 infection: Experience from a UK Regional infectious diseases Unit.68 例连续评估的 COVID-19 感染患者:来自英国一个地区传染病科的经验。
Influenza Other Respir Viruses. 2020 Jul;14(4):374-379. doi: 10.1111/irv.12739. Epub 2020 Apr 8.
6
COVID-19 and mycoplasma pneumoniae coinfection.新型冠状病毒肺炎与支原体肺炎合并感染
Am J Hematol. 2020 Jun;95(6):723-724. doi: 10.1002/ajh.25785. Epub 2020 Apr 3.
7
: A Potentially Severe Infection.一种潜在的严重感染。
J Clin Med Res. 2018 Jul;10(7):535-544. doi: 10.14740/jocmr3421w. Epub 2018 Jun 4.
8
Mycoplasma pneumoniae from the Respiratory Tract and Beyond.来自呼吸道及其他部位的肺炎支原体
Clin Microbiol Rev. 2017 Jul;30(3):747-809. doi: 10.1128/CMR.00114-16.
9
Mycoplasma pneumonia: Clinical features and management.支原体肺炎:临床特征与管理
Lung India. 2010 Apr;27(2):75-85. doi: 10.4103/0970-2113.63611.
10
Cytokines in Mycoplasma pneumoniae infections.肺炎支原体感染中的细胞因子
Cytokine Growth Factor Rev. 2004 Apr-Jun;15(2-3):157-68. doi: 10.1016/j.cytogfr.2004.01.001.